For Immediate Release
ZYLOTRIM, PARTICIPATES IN ERSP FORUM
ERSP Finds Support for Certain Claims, Recommends Marketer Modify or Discontinue Others
ERSP concluded that the marketer’s evidence did not adequately support the claim that the product is “Clinically proven to more than double the activity of fat burning enzymes” or that ”80% of each pound that was lost was pure body fat” and recommended that these claims be either modified or discontinued. Finally, ERSP determined that the “Rated #1 Weight Loss Active Ingredient” claim is inaccurate and should be either modified or discontinued in the current context in which the claim is presented in the advertising and on the product packaging.
The company, in its marketer’s statement said “… it certainly respects ERSP’s conclusions and recommendations and will modify these claims in future advertising.”
The Electronic Retailing Self-Regulation Program (ERSP) has determined that Zylotrim, LLC, which markets the Zylotrim Weight Loss Supplement, has provided reliable support for certain establishment claims but
recommended the marketer modify or discontinue others. The marketer’s advertising came to ERSP’s attention pursuant to its ongoing monitoring efforts. ERSP, the electronic direct-response industry’s self-regulatory forum, is administered by the Council of Better Business Bureaus (CBBB).
ERSP’s inquiry focused on claims included in broadcast and online advertising. Claims at issue in the ERSP inquiry included:
“Zylotrim will more than double the activity level of your fat burning enzymes making it easier to lose pounds of body fat and weight.”
”Clinically proven to more than double the activity of fat burning enzymes.”
“Clinically proven to help reduce body fat & weight.”
“Lose 200% more weight-clinically proven” / “In a recent double blind study participants who took Zylotrim lost 200% more weight than those who didn’t take it.”
“80% of each pound that was lost was pure body fat.”
“Rated #1 weight loss active ingredient.”
Following its review of the evidence, ERSP determined that the two controlled clinical human studies on 3-acetyl-7-oxo-dehydroepiandrosterone, or 7-Keto DHEA, provided reliable support for the marketer’s establishment claim of 200% increased weight loss when using the product in combination with diet and exercise as compared to subjects who simply dieted and exercised. Additionally, ERSP determined the marketer provided a reasonable basis for the claim that the product
has been “Clinically proven to help reduce body fat & weight.”